Valeant Pharmaceuticals International Inc (VRX)

26.27
0.38 1.50
NYSE : Health Care
Prev Close 25.89
Open 26.00
Day Low/High 25.69 / 26.49
52 Wk Low/High 18.55 / 206.51
Volume 11.97M
Avg Volume 25.87M
Exchange NYSE
Shares Outstanding 347.54M
Market Cap 9.63B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Trending Tickers: TWTR, VRX, ENDP, RIG

Trending Tickers: TWTR, VRX, ENDP, RIG

It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.

Andrew Left Says Trump and Clinton Agree on Just One Thing

Andrew Left Says Trump and Clinton Agree on Just One Thing

Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.

Valeant Needs Time If It Is to Recover and Rise

Valeant Needs Time If It Is to Recover and Rise

Valeant Pharmaceuticals hasn't convinced buyers to return, that's what my charts say.

Valeant (VRX) Stock Higher on Potential $1 Billion iNova Sale

Valeant (VRX) Stock Higher on Potential $1 Billion iNova Sale

Valeant (VRX) stock was rising Wednesday afternoon as it reportedly puts its iNova unit up for sale.

Cramer: What a Revoltin' Market Development This Is

Cramer: What a Revoltin' Market Development This Is

Stocks rally and then get smacked down in this inconsistent atmosphere.

Valeant's $1.5 Billion 'Capital Hole' -- and $31 Billion in Debt

Valeant's $1.5 Billion 'Capital Hole' -- and $31 Billion in Debt

It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

Stressed Out: Valeant May Need $1.5B New Debt to Fill 'Capital Hole'

It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.

Valeant (VRX) Stock Receives 'Hold' Rating at Deutsche Bank

Valeant (VRX) Stock Receives 'Hold' Rating at Deutsche Bank

Valeant (VRX) stock coverage was reinstated at Deutsche Bank on Tuesday morning.

Guggenheim Analyst Chen Takes Bullish Outlook On Valeant's (VRX) Growth Potential

Guggenheim Analyst Chen Takes Bullish Outlook On Valeant's (VRX) Growth Potential

Guggenheim Securities Pharmaceutical Analyst Louise Chen told CNBC on Wednesday that she thinks the stock has a high near-term growth potential.

Delivering Alpha -- and Animosity: Conference Speakers Agree on Little

Delivering Alpha -- and Animosity: Conference Speakers Agree on Little

The celebrity panelists seemed to butt heads on nearly every issue, except maybe on Donald Trump.

Top Stock Picks From CNBC's Delivering Alpha Conference

Top Stock Picks From CNBC's Delivering Alpha Conference

Prominent investors relay their top stock picks from today's CNBC Delivering Alpha Conference.

Valeant Pharmaceuticals (VRX) Stock Down, CEO Papa Mulls Asset Sales

Valeant Pharmaceuticals (VRX) Stock Down, CEO Papa Mulls Asset Sales

Valeant Pharmaceuticals (VRX) CEO Joseph Papa said on Tuesday that the company is considering additional non-core property sales

Cramer: We Need to Be Able to Predict a Clear Election Winner

Cramer: We Need to Be Able to Predict a Clear Election Winner

Without it, the uncertainty would be incredible between now and November.

Perrigo Shares Spike After Starboard's Smith Urges Asset Sales

Perrigo Shares Spike After Starboard's Smith Urges Asset Sales

Perrigo is the second drug company that the activist has targeted in recent months after it rejected an unsolicited bid.

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Pet Pharma Is the Newest Growth Sector

Pet Pharma Is the Newest Growth Sector

Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.

Nervous Pooch? There's a Drug for That

Nervous Pooch? There's a Drug for That

Zoetis is not averse to a little noise as investors, analysts take notice.

Valeant Pharmaceuticals (VRX) CEO Papa Plans to Sell Non-Core Assets

Valeant Pharmaceuticals (VRX) CEO Papa Plans to Sell Non-Core Assets

Valeant Pharmaceuticals (VRX) CEO Joseph Papa is helping the company to unload its debt by looking into selling non-core assets, he told CNBC's Meg Tirrell.

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis Remains Attractive Alternative Healthcare Investment

Zoetis' valuation doesn't reflect opportunities from innovation, operational improvements, and capital allocation, according to one analyst.

Chipotle May Further Franchise, Prep for Sale as Ackman Launches Campaign

Chipotle May Further Franchise, Prep for Sale as Ackman Launches Campaign

Pershing Square said it intends to engage in discussions with Chipotle about its strategic plans, which suggests the fund could push the restaurant chain into more franchising or a sale.

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

RELISTOR Tablets FDA-Approved for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Allergan CEO: No More Predatory Drug Pricing

Allergan CEO: No More Predatory Drug Pricing

CEO Brent Saunders said Allergan will act differently, pledging to limit price increases on drugs the company sells as part of a 'commitment to innovation, access and responsible pricing ideals.'

Trending Tickers: MYL, MNK, VRX, CHK, UA

Trending Tickers: MYL, MNK, VRX, CHK, UA

Rising oil prices helped buoy U.S. markets Friday.

Big Pharma's Punishment in Court of Public Opinion

Big Pharma's Punishment in Court of Public Opinion

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.

2 Biotechs to Watch Ahead of the Election

2 Biotechs to Watch Ahead of the Election

These 2 small-caps have strong pipelines and are becoming analyst darlings.